Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Drug resistance to a range of antimalarial treatments has become widespread in Africa, South
East Asia and South America. Because the rapid spread of drug resistance threatens a public
health disaster in these areas of the world and to comply with the WHO-Roll Back Malaria
policy of using Artemisinin-based combination therapies (ACT), there is a need to develop
new, safe, effective and affordable ACT.
Chlorproguanil-dapsone-artesunate (CDA)is a new ACT that is being developed for the treatment
of uncomplicated falciparum malaria in Africa.